Becker Capital Management Inc. Cuts Holdings in Pfizer Inc. $PFE

Becker Capital Management Inc. decreased its position in Pfizer Inc. (NYSE:PFE) by 14.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 325,863 shares of the biopharmaceutical company’s stock after selling 54,103 shares during the quarter. Becker Capital Management Inc.’s holdings in Pfizer were worth $8,303,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PFE. Grey Fox Wealth Advisors LLC acquired a new stake in shares of Pfizer during the 3rd quarter worth about $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer during the 2nd quarter worth $30,000. Darwin Wealth Management LLC acquired a new stake in shares of Pfizer during the second quarter worth about $32,000. Evelyn Partners Asset Management Ltd purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $33,000. Finally, True Wealth Design LLC grew its position in Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 974 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the topic of several recent analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Wolfe Research set a $24.00 price target on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Morgan Stanley cut their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research note on Monday. Finally, Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.05.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase‑3 PADCEV readout with Astellas — Reinforces oncology revenue potential and a meaningful non‑COVID growth driver for Pfizer. PADCEV Phase 3 Results
• Positive Sentiment: Argus upgraded PFE to Buy with a $35 target — analyst upgrade provides a bullish catalyst and a sizable upside target versus current levels. Argus Upgrade
• Positive Sentiment: Technical/institutional interest and yield attract traders — social and data signals point to technical recovery, notable options activity and institutional buying that support near‑term demand. Technical & Institutional Interest
• Neutral Sentiment: TD Cowen conference presentation transcript available — may contain management commentary on guidance, pipeline timelines and margin outlook; useful for parsing near‑term execution plans. TD Cowen Transcript
• Neutral Sentiment: Partner Valneva investor activity — Valneva highlights upcoming VLA15 readout, which Pfizer as partner will report; outcome could be a minor catalyst or non‑event depending on results. Valneva Investor Conferences
• Negative Sentiment: Pfizer withdrew Zumrad EMA filing — regulatory setback that delays potential European approval and associated revenue; markets view this as an immediate negative for near‑term pipeline commercialization. Zumrad EMA Withdrawal
• Negative Sentiment: CEO flags issues with FDA vaccine leadership — signals regulatory friction that could slow vaccine approvals or complicate interactions with the U.S. regulator, adding execution risk. CEO Comments on FDA
• Negative Sentiment: Analyst/coverage notes highlight headwinds — coverage points to flat guidance, falling COVID product sales and looming patent cliffs that cap upside and justify cautious positioning by some investors. Analyst Concerns

Pfizer Stock Performance

NYSE:PFE opened at $27.28 on Tuesday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The firm has a 50-day moving average of $26.17 and a two-hundred day moving average of $25.43. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock has a market cap of $155.12 billion, a P/E ratio of 20.06 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.63 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.